139 related articles for article (PubMed ID: 2535968)
1. The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small-cell lung cancer and neuroblastoma grown as multicellular spheroids.
Russell J; Adam J; Wheldon TE; Kaye SB
Cancer Chemother Pharmacol; 1989; 23(2):111-4. PubMed ID: 2535968
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of cis-platin and carboplatin in the chemotherapy of squamous cell carcinoma grown as multicellular spheroids.
Schwachöfer JH; Crooijmans RP; Hoogenhout J; Kal HB; Theeuwes AG
Anticancer Res; 1990; 10(3):805-11. PubMed ID: 2195988
[TBL] [Abstract][Full Text] [Related]
3. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
Steerenberg PA; Vendrik CP; de Jong WH; de Groot G; Fichtinger-Schepman AM; Scheefhals AP; Schornagel JH
Cancer Chemother Pharmacol; 1988; 22(1):51-7. PubMed ID: 3293840
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro.
Harstrick A; Casper J; Guba R; Wilke H; Poliwoda H; Schmoll HJ
Cancer; 1989 Mar; 63(6):1079-83. PubMed ID: 2645036
[TBL] [Abstract][Full Text] [Related]
5. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs.
Vendrik CP; de Jong WH; Van der Minnen AC; Fichtinger-Schepman AM; Steerenberg PA; Schornagel JH
Anticancer Res; 1990; 10(2A):447-52. PubMed ID: 2346318
[TBL] [Abstract][Full Text] [Related]
6. Cross resistance studies with L1210 leukemia subline single and double resistant to cisplatin and iproplatin (CHIP).
Hrubisko M; Ujházy V
Neoplasma; 1990; 37(6):631-8. PubMed ID: 2274083
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of pre-mRNA splicing by cisplatin and platinum analogs.
Schmittgen TD; Ju JF; Danenberg KD; Danenberg PV
Int J Oncol; 2003 Sep; 23(3):785-9. PubMed ID: 12888918
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
9. Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis.
Müller LJ; Moorer-van Delft CM; Roubos EW; Vermorken JB; Boer HH
Cancer Res; 1992 Feb; 52(4):963-73. PubMed ID: 1737358
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of cisplatin and cisdiammine-1,1-cyclobutane dicarboxylate in MGH-U1 cells grown as monolayers, spheroids, and xenografts.
Erlichman C; Vidgen D; Wu A
J Natl Cancer Inst; 1985 Sep; 75(3):499-505. PubMed ID: 3897683
[TBL] [Abstract][Full Text] [Related]
11. The effect of second generation platinum cytostatics on mammalian cell proliferation.
Keprtová J; Smutná A; Minárová E; Vrána O
Neoplasma; 1990; 37(2):121-9. PubMed ID: 2188163
[TBL] [Abstract][Full Text] [Related]
12. In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin.
Takahashi H; Sasaki Y; Saijo N; Sakurai M; Nakano H; Nakagawa K; Hoshi A; Jett JR; Hong WS
Cancer Chemother Pharmacol; 1987; 19(3):197-200. PubMed ID: 3034444
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
15. Comparative cytotoxicity between cisplatin and second generation platinum analogs.
Drewinko B; Yang LY; Trujillo JM
Invest New Drugs; 1985; 3(4):335-40. PubMed ID: 3910609
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II evaluation of iproplatin (CHIP) and carboplatin (CBDCA) in lung cancer. A Southeastern Cancer Study Group trial.
Kramer BS; Birch R; Greco A; Prestridge K; DeSimone P; Omura G
Am J Clin Oncol; 1988 Dec; 11(6):643-5. PubMed ID: 2847524
[TBL] [Abstract][Full Text] [Related]
17. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
Jones AC; Wilson PA; Steel GG
Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788
[TBL] [Abstract][Full Text] [Related]
18. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a new platinum compound (glycolate-o,o') diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system.
Kanzawa F; Matsushima Y; Nakano H; Nakagawa K; Takahashi H; Sasaki Y; Saijo N
Anticancer Res; 1988; 8(3):323-7. PubMed ID: 2839098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
